Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Activation of the Amino Acid Response Pathway Blunts the Effects of Cardiac Stress.

Qin P, Arabacilar P, Bernard RE, Bao W, Olzinski AR, Guo Y, Lal H, Eisennagel SH, Platchek MC, Xie W, Del Rosario J, Nayal M, Lu Q, Roethke T, Schnackenberg CG, Wright F, Quaile MP, Halsey WS, Hughes AM, Sathe GM, Livi GP, Kirkpatrick RB, Qu XA, Rajpal DK, Faelth Savitski M, Bantscheff M, Joberty G, Bergamini G, Force TL, Gatto GJ Jr, Hu E, Willette RN.

J Am Heart Assoc. 2017 May 9;6(5). pii: e004453. doi: 10.1161/JAHA.116.004453.

2.

Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice.

Morgan LA, Olzinski AR, Upson JJ, Zhao S, Wang T, Eisennagel SH, Hoang B, Tunstead JR, Marino JP Jr, Willette RN, Jucker BM, Behm DJ.

J Cardiovasc Pharmacol. 2013 Apr;61(4):291-301. doi: 10.1097/FJC.0b013e31827fe59c.

PMID:
23232840
3.

An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure.

Thorneloe KS, Cheung M, Bao W, Alsaid H, Lenhard S, Jian MY, Costell M, Maniscalco-Hauk K, Krawiec JA, Olzinski A, Gordon E, Lozinskaya I, Elefante L, Qin P, Matasic DS, James C, Tunstead J, Donovan B, Kallal L, Waszkiewicz A, Vaidya K, Davenport EA, Larkin J, Burgert M, Casillas LN, Marquis RW, Ye G, Eidam HS, Goodman KB, Toomey JR, Roethke TJ, Jucker BM, Schnackenberg CG, Townsley MI, Lepore JJ, Willette RN.

Sci Transl Med. 2012 Nov 7;4(159):159ra148. doi: 10.1126/scitranslmed.3004276.

4.

Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress.

Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, Maniscalco K, Olzinski AR, Ballard VL, Herry K, Grondin P, Dodic N, Mirguet O, Bouillot A, Gellibert F, Coatney RW, Lepore JJ, Jucker BM, Jolivette LJ, Willette RN, Schnackenberg CG, Behm DJ.

Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012.

5.

CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.

Wang GZ, Haile PA, Daniel T, Belot B, Viet AQ, Goodman KB, Sha D, Dowdell SE, Varga N, Hong X, Chakravorty S, Webb C, Cornejo C, Olzinski A, Bernard R, Evans C, Emmons A, Briand J, Chung CW, Quek R, Lee D, Gough PJ, Sehon CA.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7291-4. doi: 10.1016/j.bmcl.2011.10.038. Epub 2011 Oct 19.

PMID:
22047688
6.

GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.

Behm DJ, Aiyar NV, Olzinski AR, McAtee JJ, Hilfiker MA, Dodson JW, Dowdell SE, Wang GZ, Goodman KB, Sehon CA, Harpel MR, Willette RN, Neeb MJ, Leach CA, Douglas SA.

Br J Pharmacol. 2010 Sep;161(1):207-28. doi: 10.1111/j.1476-5381.2010.00889.x.

7.

Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat.

Bao W, Qin P, Needle S, Erickson-Miller CL, Duffy KJ, Ariazi JL, Zhao S, Olzinski AR, Behm DJ, Pipes GC, Jucker BM, Hu E, Lepore JJ, Willette RN.

J Cardiovasc Pharmacol. 2010 Aug;56(2):147-55. doi: 10.1097/FJC.0b013e3181e2bfef.

PMID:
20714241
8.

Pharmacological inhibition of C-C chemokine receptor 2 decreases macrophage infiltration in the aortic root of the human C-C chemokine receptor 2/apolipoprotein E-/- mouse: magnetic resonance imaging assessment.

Olzinski AR, Turner GH, Bernard RE, Karr H, Cornejo CA, Aravindhan K, Hoang B, Ringenberg MA, Qin P, Goodman KB, Willette RN, Macphee CH, Jucker BM, Sehon CA, Gough PJ.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):253-9. doi: 10.1161/ATVBAHA.109.198812. Epub 2009 Dec 3. Erratum in: Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):e170.

PMID:
19965779
9.

In vivo serial assessment of aortic aneurysm formation in apolipoprotein E-deficient mice via MRI.

Turner GH, Olzinski AR, Bernard RE, Aravindhan K, Karr HW, Mirabile RC, Willette RN, Gough PJ, Jucker BM.

Circ Cardiovasc Imaging. 2008 Nov;1(3):220-6. doi: 10.1161/CIRCIMAGING.108.787358. Epub 2008 Sep 17.

PMID:
19808546
10.

Assessment of macrophage infiltration in a murine model of abdominal aortic aneurysm.

Turner GH, Olzinski AR, Bernard RE, Aravindhan K, Boyle RJ, Newman MJ, Gardner SD, Willette RN, Gough PJ, Jucker BM.

J Magn Reson Imaging. 2009 Aug;30(2):455-60. doi: 10.1002/jmri.21843.

PMID:
19629967
11.

Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.

Willette RN, Eybye ME, Olzinski AR, Behm DJ, Aiyar N, Maniscalco K, Bentley RG, Coatney RW, Zhao S, Westfall TD, Doe CP.

J Pharmacol Exp Ther. 2009 Sep;330(3):964-70. doi: 10.1124/jpet.109.154443. Epub 2009 Jun 25.

PMID:
19556450
12.

p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment.

Morris JB, Olzinski AR, Bernard RE, Aravindhan K, Mirabile RC, Boyce R, Willette RN, Jucker BM.

Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):265-71. Epub 2007 Dec 27.

PMID:
18162612
13.

Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study.

Jucker BM, Yang D, Casey WM, Olzinski AR, Williams C, Lenhard SC, Legos JJ, Hawk CT, Sarkar SK, Newsholme SJ.

Am J Physiol Endocrinol Metab. 2007 Nov;293(5):E1256-64. Epub 2007 Aug 28.

14.

PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure.

Jucker BM, Doe CP, Schnackenberg CG, Olzinski AR, Maniscalco K, Williams C, Hu TC, Lenhard SC, Costell M, Bernard R, Sarov-Blat L, Steplewski K, Willette RN.

J Cardiovasc Pharmacol. 2007 Jul;50(1):25-34.

PMID:
17666912
15.

P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1.

Nerurkar SS, Olzinski AR, Frazier KS, Mirabile RC, O'Brien SP, Jing J, Rajagopalan D, Yue TL, Willette RN.

Biomarkers. 2007 Jan-Feb;12(1):87-112.

PMID:
17438656
16.

Rosiglitazone protects against ischemia/reperfusion-induced leukocyte adhesion in the zucker diabetic fatty rat.

Johns DG, Ao Z, Eybye M, Olzinski A, Costell M, Gruver S, Smith SA, Douglas SA, Macphee CH.

J Pharmacol Exp Ther. 2005 Dec;315(3):1020-7. Epub 2005 Aug 25.

PMID:
16123307
17.

Synthetic LXR agonists increase LDL in CETP species.

Groot PH, Pearce NJ, Yates JW, Stocker C, Sauermelch C, Doe CP, Willette RN, Olzinski A, Peters T, d'Epagnier D, Morasco KO, Krawiec JA, Webb CL, Aravindhan K, Jucker B, Burgert M, Ma C, Marino JP, Collins JL, Macphee CH, Thompson SK, Jaye M.

J Lipid Res. 2005 Oct;46(10):2182-91. Epub 2005 Jul 16.

18.

Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling.

Yancy AD, Olzinski AR, Hu TC, Lenhard SC, Aravindhan K, Gruver SM, Jacobs PM, Willette RN, Jucker BM.

J Magn Reson Imaging. 2005 Apr;21(4):432-42.

PMID:
15779033
19.

Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection.

Olzinski AR, McCafferty TA, Zhao SQ, Behm DJ, Eybye ME, Maniscalco K, Bentley R, Frazier KS, Milliner CM, Mirabile RC, Coatney RW, Willette RN.

Cardiovasc Res. 2005 Apr 1;66(1):170-8. Epub 2005 Jan 28.

PMID:
15769460
20.

Cathepsin S expression is up-regulated following balloon angioplasty in the hypercholesterolemic rabbit.

Burns-Kurtis CL, Olzinski AR, Needle S, Fox JH, Capper EA, Kelly FM, McQueney MS, Romanic AM.

Cardiovasc Res. 2004 Jun 1;62(3):610-20.

PMID:
15158154
21.

p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension.

Ju H, Behm DJ, Nerurkar S, Eybye ME, Haimbach RE, Olzinski AR, Douglas SA, Willette RN.

J Pharmacol Exp Ther. 2003 Dec;307(3):932-8. Epub 2003 Oct 15.

PMID:
14561851
22.

Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury.

Ju H, Nerurkar S, Sauermelch CF, Olzinski AR, Mirabile R, Zimmerman D, Lee JC, Adams J, Sisko J, Berova M, Willette RN.

J Pharmacol Exp Ther. 2002 Apr;301(1):15-20.

PMID:
11907152
23.

Functional venous anatomy for right-lobe grafting and techniques to optimize outflow.

Marcos A, Orloff M, Mieles L, Olzinski AT, Renz JF, Sitzmann JV.

Liver Transpl. 2001 Oct;7(10):845-52.

24.

Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.

Willette RN, Anderson KM, Nelson AH, Olzinski AR, Woods T, Coatney RW, Aiyar N, Ohlstein EH, Barone FC.

J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17.

PMID:
11588531
25.

Reconstruction of double hepatic arterial and portal venous branches for right-lobe living donor liver transplantation.

Marcos A, Orloff M, Mieles L, Olzinski A, Sitzmann J.

Liver Transpl. 2001 Aug;7(8):673-9.

26.

Adult-to-adult living donor liver transplantation.

Olzinski AT, Marcos A.

Curr Gastroenterol Rep. 2001 Feb;3(1):65-70. Review.

PMID:
11177697
27.

The interrelationship between portal and arterial blood flow after adult to adult living donor liver transplantation.

Marcos A, Olzinski AT, Ham JM, Fisher RA, Posner MP.

Transplantation. 2000 Dec 27;70(12):1697-703.

PMID:
11152099
28.

Selection and outcome of living donors for adult to adult right lobe transplantation.

Marcos A, Fisher RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Olbrisch ME, Posner MP.

Transplantation. 2000 Jun 15;69(11):2410-5.

PMID:
10868650
29.

Emergency portacaval shunt for control of hemorrhage from a parenchymal fracture after adult-to-adult living donor liver transplantation.

Marcos A, Fisher RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Posner MP.

Transplantation. 2000 May 27;69(10):2218-21.

PMID:
10852631
30.

Emergency adult to adult living donor liver transplantation for fulminant hepatic failure.

Marcos A, Ham JM, Fisher RA, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Posner MP.

Transplantation. 2000 May 27;69(10):2202-5.

PMID:
10852626
31.

Single-center analysis of the first 40 adult-to-adult living donor liver transplants using the right lobe.

Marcos A, Ham JM, Fisher RA, Olzinski AT, Posner MP.

Liver Transpl. 2000 May;6(3):296-301.

32.

Surgical management of anatomical variations of the right lobe in living donor liver transplantation.

Marcos A, Ham JM, Fisher RA, Olzinski AT, Posner MP.

Ann Surg. 2000 Jun;231(6):824-31.

33.

Treating Budd-Chiari Syndrome: making rational choices from a myriad of options.

Olzinski AT, Sanyal AJ.

J Clin Gastroenterol. 2000 Mar;30(2):155-61. Review.

PMID:
10730920

Supplemental Content

Loading ...
Support Center